Hilton Whittle

Hilton Whittle

Auto-generated profile, based on publicly available information

Hilton Whittle

Medical Research Council, Fajara, The Gambia

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2002 in BMJ
Verified
Journal Article
Closed access
PDF file
HWHilton Whittle
Hilton Whittle
SJShabbar Jaffar
Shabbar Jaffar
MWMichael Wansbrough
Michael Wansbrough
MMMaimuna Mendy
Maimuna Mendy
UDUga Dumpis
Uga Dumpis
AHAndrew Hall
Andrew Hall
Objective: To determine the duration of protection from hepatitis B vaccine given in infancy and early childhood. Design: Cross sectional serological study of hepatitis B virus infection in children of various ages 14 years after the start of a trial of vaccination regimens. Setting: Two villages in the Gambia. Participants: Children and adolescents given hepatitis B vaccine in infancy or early childhood: 232 were aged 1-5 years, 225 aged 5-9 years, 220 aged 10-14 years, and 175 aged 15-19 years. Main outcome measures: Vaccine efficacy against infection and against chronic infection in the different age groups. Results: Vaccine efficacy against chronic carriage of hepatitis B virus was 94% (95% confidence interval 89% to 97%), which did not vary significantly between the age groups. Efficacy against infection was 80% (76% to 84%). This was significantly lower in the oldest age group (65%, 56 to 73). Of the uninfected participants in this age group, 36% had no detectable hepatitis B virus surface antibody. Time since vaccination and a low peak antibody response were the most powerful risk factors for breakthrough infection (P<0.001 in each case). Low peak antibody response was also a risk factor for chronic carriage (odds ratio 95, 19 to 466). Conclusions: Children vaccinated in infancy are at increased risk of hepatitis B virus infection in the late teens. The risk of chronic carriage after sexual exposure needs further assessment to determine if booster vaccines are necessary.

19 May 2010 in Retrovirology
Verified
Journal Article
Open access
PDF file
MLMaarten F Schim van der Loeff
Maarten F Schim van der Loeff
NLNatasha Larke
Natasha Larke
SKSteve Kaye
Steve Kaye
NBNeil Berry
Neil Berry
KAKoya Ariyoshi
Koya Ariyoshi
HWHilton Whittle
Hilton Whittle
Background: There have been no previous studies of the long-term survival and temporal changes in plasma viral load among HIV-2 infected subjects. Methods: 133 HIV-2 infected and 158 HIV-uninfected subjects from a rural area in North-west Guinea-Bissau, West Africa were enrolled into a prospective cohort study in 1991 and followed-up to mid-2009. Data were collected on four occasions during that period on HIV antibodies, CD4% and HIV-2 plasma viral load. Results: Median age (interquartile range [IQR]) of HIV-2 infected subjects at time of enrollment was 47 (36, 60) years, similar to that of HIV-uninfected control subjects, 49 (38, 62) (p = 0.4). Median (IQR) plasma viral load and CD4 percentage were 347 (50, 4,300) copies/ml and 29 (22, 35) respectively. Overall loss to follow-up to assess vital status was small, at 6.7% and 6.3% for HIV-2 infected and uninfected subjects respectively. An additional 17 (12.8%) and 16 (10.1%) of HIV-2 infected and uninfected subjects respectively were censored during follow-up due to infection with HIV-1. The mortality rate per 100 person-years (95% CI) was 4.5 (3.6, 5.8) among HIV-2 infected subjects compared to 2.1 (1.6, 2.9) among HIV-uninfected (age-sex adjusted rate ratio 1.9 (1.3, 2.8, p < 0.001) representing a 2-fold excess mortality rate associated with HIV-2 infection. Viral load measurements were available for 98%, 78%, 77% and 61% HIV-2 infected subjects who were alive and had not become super-infected with HIV-1, in 1991, 1996, 2003 and 2006 respectively. Median plasma viral load (RNA copies per ml) (IQR) did not change significantly over time, being 150 (50, 1,554; n = 77) in 1996, 203 (50, 2,837; n = 47) in 2003 and 171 (50, 497; n = 31) in 2006. Thirty seven percent of HIV-2 subjects had undetectable viraemia (<100 copies/ml) at baseline: strikingly, mortality in this group was similar to that of the general population. Conclusions: A substantial proportion of HIV-2 infected subjects in this cohort have stable plasma viral load, and those with an undetectable viral load (37%) at study entry had a normal survival rate. However, the sequential laboratory findings need to be interpreted with caution given the number of individuals who could not be re-examined.

1 July 2001 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SASowsan F. Atabani
Sowsan F. Atabani
ABAdriana A. Byrnes
Adriana A. Byrnes
AJAssan Jaye
Assan Jaye
IKI. Michael Kidd
I. Michael Kidd
AMAlbert F. Magnusen
Albert F. Magnusen
CKChristopher L. Karp
Christopher L. Karp
Among vaccine-preventable diseases, measles is the preeminent killer of children worldwide. Infection with measles virus (MV) is associated with prol

15 September 2010 in Virology Journal
Verified
Journal Article
Open access
PDF file
MJModou Lamin Jobarteh
Modou Lamin Jobarteh
MMMarine Malfroy
Marine Malfroy
IPIngrid Peterson
Ingrid Peterson
AJAdam Jeng
Adam Jeng
RSRamu Sarge-Njie
Ramu Sarge-Njie
MMMaimuna Mendy
Maimuna Mendy
Background: The prevalence of HIV/hepatitis co-infection in sub-Saharan Africa is not well documented, while both HIV and HBV are endemic in this area.Objective: The aim of this study is to determine the seroprevalence of HBV and HCV virus in HIV-infected subjects in the Gambia.Methods: Plasma samples from HIV infected patients (190 individuals with clinically defined AIDS and 382 individuals without AIDS) were tested retrospectively for the presence of HBV sero-markers and for serum HBV DNA, screened for HCV infection by testing for anti-HCV antibody and HCV RNA.Results: HBsAg prevalence in HIV-positive individuals is 12.2%. HIV/HBV co-infected individuals with CD4 count of <200 cells uL-1 have a higher HBV DNA viral load than patients with higher CD4 count (log 4.0 vs. log 2.0 DNA copies/ml, p < 0.05). Males (OR = 1.8, 95% CI: 1.0, 3.2) were more likely to be HBsAg positive than female. HCV seroprevalence was 0.9% in HIV-positive individuals.Conclusion: The prevalence of HBsAg carriage in HIV- infected Gambians is similar to that obtained in the general population. However co-infected individuals with reduced CD4 levels, indicative of AIDS had higher prevalence of HBeAg retention and elevated HBV DNA levels compared to non-AIDS patients with higher CD4 count.

14 January 2010 in Malaria Journal
Verified
Journal Article
Open access
PDF file
BWBrigitte Walther
Brigitte Walther
DMDavid Jc Miles
David Jc Miles
SCSarah Crozier
Sarah Crozier
PWPauline Waight
Pauline Waight
MPMelba S Palmero
Melba S Palmero
KFKatie L Flanagan
Katie L Flanagan
Infection with Plasmodium falciparum during pregnancy contributes substantially to the disease burden in both mothers and offspring. Placental malaria may lead to intrauterine growth restriction or preterm delivery resulting in low birth weight (LBW), which, in general, is associated with increased infant morbidity and mortality. However, little is known about the possible direct impact of the specific disease processes occurring in PM on longer term outcomes such as subsequent retarded growth development independent of LBW.

1 January 1991 in AIDS
Verified
Journal Article
Closed access
JPJacques Pepin
Jacques Pepin
DDDavid Dunn
David Dunn
IGIsatou Gaye
Isatou Gaye
PAPedro Alonso
Pedro Alonso
AEArinze Egboga
Arinze Egboga
AWAndrew Wilkins
Andrew Wilkins
Three hundred and fifty-five prostitutes working in The Gambia were enrolled in a study of retroviral infections. Eight-seven (24.6%) were infected with HIV-2 only, two (0.6%) with HIV-1 only, four (1.1%) had sera showing double HIV-1/HIV-2 reactivity, and 37 (10.4%) were seropositive for HTLV-I. After allowing for socioeconomic and serological variables in a multivariate analysis, HIV-2 infection was associated with serological evidence of a previous episode of syphilis [a rapid plasma reagin (RPR) positive/Treponema pallidum haemagglutination assay (TPHA) positive; odds ratio (OR) = 2.18, 95% confidence interval (CI) = 1.19–3.98], with having antibodies against Haemophilus ducreyi (OR = 2.05, 95% CI = 0.89–4.70) or against HTLV-I (OR = 2.17, 95% CI = 0.91–5.19). HIV-2-seropositive prostitutes were three times more likely [17 out of 78 (22%) versus 15 out of 219 (7%), P < 0.001] to have generalized lymphadenopathy than those who were seronegative. These data suggest that genital ulcer diseases may facilitate the transmission of HIV-2, and that HIV-2 rapidly induces the appearance of generalized lymphadenopathy in a substantial proportion of infected individuals.